Drug intelligence / Profile preview

growth hormone + liraglutide

Development stage: Preclinical
Lead developer: Novo Nordisk
Modality: Peptides, Recombinant Proteins and Enzymes
Administration: Subcutaneous

Overview

A combination of growth hormone (GH) and liraglutide being investigated for potential effects on metabolism and diabetes management. Growth hormone is a peptide hormone that stimulates growth, cell reproduction, and regeneration, while liraglutide is a GLP-1 receptor agonist used for treating type 2 diabetes and obesity. Research has shown that while liraglutide significantly reduces food intake, improves glucose tolerance, and enhances insulin sensitivity, the addition of growth hormone does not significantly augment these beneficial effects in experimental models.

Targets

GHR (Growth hormone receptor)GLP1R (GLP-1R)

Beyond the preview

Go deeper on growth hormone + liraglutide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on growth hormone + liraglutide.

Explore the full profile